The Annual Scientific Meeting (ASM) of Breast Cancer Trials (BCT) is a premier event in breast cancer clinical trials research in Australasia. Featuring renowned speakers, the program includes scientific... ConferenceMedical & Pharma Follow1
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic featu
Go To: An Overview of Breast Cancer - Symptoms, causes and treatments 2024 Research Is levothyroxine and/or your thyroid driving your breast cancer? Modified Citrus Pectin (MCP) and cancer Salinomycin, a promising anticancer stem cell agent Changing your diet to beat cancer How sugar damages your...
165 Clinical trials evaluating the oral PARP inhibitor olaparib in BRCA1/2-positive metastatic breast cancer are currently underway, with interim results showing efficacy.167 Veliparib is another PARP inhibitor currently being evaluated in combination with paclitaxel and carboplatin for metastatic TNBC.168...
The 313-variant polygenic risk score (PRS313) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS313 across different European populations which could influence risk estimation has not been performed. We e
Despite the remarkable advances for BC therapy; it is still the most important cause of cancer-related deaths in women due to its high metastatic ability. Some subtypes of BC have a strong metastatic nature and their clinical control is a severe challenge3. Metastasis is an original ...
the preliminary efficacy (phase 1) nature of this pilot study, the results will be used to pursue larger phase II and III clinical trials to determine the efficacy of the programme in tumour suppression or regression in patients with osteolytic bone metastases secondary to breast cancer, and to...
"There are some experiments with cancer cells in culture showing some anti-cancer properties, but on checkingclinicaltrials.govjust now, the biggest clinical trial library worldwide, there appear to be no recently completed or currently ongoing studies with [HAMLET]," they said. ...
The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. Methods In total, 2298 women (≥45 years, invasive duct...
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mu